Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of INCA033989 versus best available therapy in CALR-mutated essential thrombocythemia previously treated with cytoreductive therapy
jRCT2071260097Phase 3Not yet recruiting
- Sponsor
- Incyte
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of inca033989 in thrombocythemia (2 arms), sponsored by Incyte. Primary endpoint: Durable clinicohematologic response. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
inca033989
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on jRCT2071260097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260097.